Literature DB >> 12067271

Objective improvement from base-in prisms for reading discomfort associated with mini-convergence insufficiency type exophoria in school children.

Monte Stavis1, Martha Murray, Patricia Jenkins, Robert Wood, Becky Brenham, Jennifer Jass.   

Abstract

PURPOSE: To determine whether base-in prism glasses could diminish asthenopia, and improve reading abilities (speed, accuracy and comprehension).
METHODS: All patients aged 8-18 years, from one practice, were examined and considered prospectively over a six month period. Ten percent (72) of these 703 patients met initial criteria of an exodeviation greater at near than distance and reading discomfort. At initial examination these 72 were asked to read orally, with and without base-in prisms. If the senior examiner noted they read faster and with fewer mistakes, and the patient reported increased reading comfort, then reading (only) glasses with 2 to 3 diopters base-in prism OU were prescribed. Of the 72, 33 were so treated. After 3 weeks they were given the Gray Oral Reading Test (GORT-3). This test has two equal parts which were administered one with, and one without, prisms. A subjective questionnaire was also administered.
RESULTS: The overall mean improvement in reading speed, accuracy and comprehension on the GORT- 3 with base-in prisms, was from the 34th to the 66th percentile. The improvements in reading were "statistically significant" at p<.001. Patients also reported subjective improvement in asthenopic symptoms and headaches.
CONCLUSION: Base-in prism glasses improve subjective reading comfort and abilities (speed, accuracy and comprehension) in these patients.

Entities:  

Mesh:

Year:  2002        PMID: 12067271

Source DB:  PubMed          Journal:  Binocul Vis Strabismus Q        ISSN: 1088-6281


  9 in total

1.  Intermittent exotropia increasing with near fixation: a "soft" sign of neurological disease.

Authors:  P H Phillips; K J Fray; M C Brodsky
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

2.  Randomised clinical trial of the effectiveness of base-in prism reading glasses versus placebo reading glasses for symptomatic convergence insufficiency in children.

Authors:  M Scheiman; S Cotter; M Rouse; G L Mitchell; M Kulp; J Cooper; E Borsting
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

3.  Intermittent exotropia increasing with near fixation: a "soft" sign of neurological disease.

Authors:  P H Phillips; K J Fray; M C Brodsky
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

Review 4.  Non-surgical interventions for convergence insufficiency.

Authors:  Mitchell Scheiman; Jane Gwiazda; Tianjing Li
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

5.  Treatment of convergence insufficiency in childhood: a current perspective.

Authors:  Mitchell Scheiman; Michael Rouse; Marjean Taylor Kulp; Susan Cotter; Richard Hertle; G Lynn Mitchell
Journal:  Optom Vis Sci       Date:  2009-05       Impact factor: 1.973

6.  Spherical lenses and prisms lead to postural instability in both dyslexic and non dyslexic adolescents.

Authors:  Zoi Kapoula; Chrystal Gaertner; Eric Matheron
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

7.  An evaluation of clinical treatment of convergence insufficiency for children with reading difficulties.

Authors:  Wolfgang A Dusek; Barbara K Pierscionek; Julie F McClelland
Journal:  BMC Ophthalmol       Date:  2011-08-11       Impact factor: 2.209

8.  Early results of slanted recession of the lateral rectus muscle for intermittent exotropia with convergence insufficiency.

Authors:  Bo Young Chun; Kyung Min Kang
Journal:  J Ophthalmol       Date:  2015-01-26       Impact factor: 1.909

9.  Comparison of surgical outcomes of slanted procedure for exotropia with convergence insufficiency according to their response to preoperative monocular occlusion.

Authors:  Bo Young Chun; Jun Ho Oh; Hyung Jun Choi
Journal:  Sci Rep       Date:  2020-04-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.